TOXICOLOGICAL PROFILE FOR
POLYCYCLIC AROMATIC HYDROCARBONS

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

August 1995
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
UPDATE STATEMENT

A Toxicological Profile for Polycyclic Aromatic Hydrocarbons was released in December 1990. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801).
Foreword

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and Disease Registry
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):  
Moiz Mumtaz, Ph.D.  
ATSDR, Division of Toxicology, Atlanta, GA

Julia George, Ph.D.  
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:


2. Health Effects Review. The Healths Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.
A peer review panel was assembled for the PAHs. The panel consisted of the following members:

1. Dr. Gail Charnley, Consultant in Toxicology, Arlington, Virginia;

2. Dr. Edmond LaVoie, Professor, Rutgers University College of Pharmacy, Piscataway, New Jersey; and

3. Dr. Alexander Wood, Distinguished Research Leader and Director, Department of Oncology, Hoffmann-LaRoche, Inc., Nutley, New Jersey.

These experts collectively have knowledge of the polycyclic aromatic hydrocarbons’ physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers’ comments and determined which comments will be included in the profile. A listing of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile’s final content. The responsibility for the content of this profile lies with the ATSDR.
## CONTENTS

**FOREWORD** ................................................................. v

**CONTRIBUTORS** ........................................................ v

**PEER REVIEW** ................................................................ ix

**LIST OF FIGURES** ......................................................... xv

**LIST OF TABLES** ........................................................ xvii

1. **PUBLIC HEALTH STATEMENT** ..................................... 1
   - 1.1 WHAT ARE POLYCYCLIC AROMATIC HYDROCARBONS? .......... 1
   - 1.2 WHAT HAPPENS TO POLYCYCLIC AROMATIC HYDROCARBONS WHEN THEY ENTER THE ENVIRONMENT? ..................... 3
   - 1.3 HOW MIGHT I BE EXPOSED TO POLYCYCLIC AROMATIC HYDROCARBONS? .......................................................... 3
   - 1.4 HOW CAN POLYCYCLIC AROMATIC HYDROCARBONS ENTER AND LEAVE MY BODY? .................................................. 5
   - 1.5 HOW CAN POLYCYCLIC AROMATIC HYDROCARBONS AFFECT MY HEALTH? .......................................................... 6
   - 1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO POLYCYCLIC AROMATIC HYDROCARBONS? 7
   - 1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .......................... 7
   - 1.8 WHERE CAN I GET MORE INFORMATION? ....................... 9

2. **HEALTH EFFECTS** ..................................................... 11
   - 2.1 INTRODUCTION ....................................................... 11
   - 2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 11
     - 2.2.1 Inhalation Exposure ............................................. 15
       - 2.2.1.1 Death ....................................................... 15
       - 2.2.1.2 Systemic Effects ........................................... 16
       - 2.2.1.3 Immunological and Lymphoreticular Effects ......... 19
       - 2.2.1.4 Neurological Effects ..................................... 20
       - 2.2.1.5 Reproductive Effects ................................... 20
       - 2.2.1.6 Developmental Effects .................................. 20
       - 2.2.1.7 Genotoxic Effects ........................................ 20
       - 2.2.1.8 Cancer ..................................................... 22
     - 2.2.2 Oral Exposure .................................................. 23
       - 2.2.2.1 Death ....................................................... 23
       - 2.2.2.2 Systemic Effects ........................................... 24
       - 2.2.2.3 Immunological and Lymphoreticular Effects ......... 40
       - 2.2.2.4 Neurological Effects ..................................... 41
       - 2.2.2.5 Reproductive Effects ................................... 41
       - 2.2.2.6 Developmental Effects .................................. 43
       - 2.2.2.7 Genotoxic Effects ........................................ 45
       - 2.2.2.8 Cancer ..................................................... 49
LIST OF FIGURES

2-1 Levels of Significant Exposure to Polycyclic Aromatic Hydrocarbons - Inhalation .......................... 18
2-2 Levels of Significant Exposure to Polycyclic Aromatic Hydrocarbons - Oral ................................. 32
2-3 Proposed Metabolic Scheme for Benzo[a]pyrene ................................................................. 93
2-4 Proposed Metabolic Scheme for Benzo[b]fluoranthene .......................................................... 100
2-5 Existing Information on Health Effects of Polycyclic Aromatic Hydrocarbons ......................... 193
5-1 Frequency of NPL Sites with PAHs Contamination ................................................................. 231
LIST OF TABLES

2-1  Levels of Significant Exposure to Polycyclic Aromatic Hydrocarbons - Inhalation ............ 17
2-2  Levels of Significant Exposure to Polycyclic Aromatic Hydrocarbons - Oral .................. 25
2-3  Levels of Significant Exposure to Polycyclic Aromatic Hydrocarbons - Dermal ................ 54
2-4  Genotoxicity of Polycyclic Aromatic Hydrocarbons *In Vivo* ....................................... 133
2-5  Genotoxicity of Polycyclic Aromatic Hydrocarbons *In Vitro* ..................................... 139
2-6  Summary of Carcinogenicity Studies with Polycyclic Aromatic Hydrocarbons
    Using Parenteral Routes of Exposure .................................................................................. 165
2-7  Ongoing Studies on Polycyclic Aromatic Hydrocarbons .................................................. 207
3-1  Chemical Identity of Polycyclic Aromatic Hydrocarbons ................................................. 210
3-2  Physical and Chemical Properties of Polycyclic Aromatic Hydrocarbons ......................... 216
4-1  Facilities That Manufacture or Process Anthracene ......................................................... 224
5-1  Releases to the Environment From Facilities That Manufacture or Process Anthracene .... 233
5-2  Polycyclic Aromatic Hydrocarbons (PAHs) Bioconcentration Factors (BCFs) for
    Selected Species of Aquatic Organisms ............................................................................. 242
5-3  Background Soil Concentrations of Polycyclic Aromatic Hydrocarbons (PAHs) .................. 262
5-4  Soil Concentrations Polycyclic Aromatic Hydrocarbons (PAHs) at Contaminated Sites .... 263
5-5  Concentrations of Some Polycyclic Aromatic Hydrocarbons (PAHs) in Tobacco Smoke .... 272
5-6  Average Indoor Concentrations of Polycyclic Aromatic Hydrocarbons (PAHs) in Different
    Categories of Sample Homes Occupied by Smokers and Non-smokers ......................... 276
5-7  Fish Consumption Advisories ............................................................................................ 283
6-1  Analytical Methods for Determining Polycyclic Aromatic Hydrocarbons
    in Biological Samples ........................................................................................................ 292
6-2  Analytical Methods for Determining Polycyclic Aromatic Hydrocarbons
    in Environmental Samples .................................................................................................... 307
7-1  Regulations and Guidelines Applicable to Polycyclic
    Aromatic Hydrocarbons ........................................................................................................ 329